Mechanism, dosage tables by route, reconstitution guide, IBD research data, stacking context, and COA-verified vendor pricing — all in one place.
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH). It exerts anti-inflammatory effects primarily through melanocortin receptor 1 (MC1R) binding, downstream NF-κB suppression, and inhibition of pro-inflammatory cytokine production. It is one of the few peptides with demonstrated activity via oral delivery to gut tissue.
| Property | Value |
|---|---|
| Full name | Lysine-Proline-Valine (KPV) |
| Parent peptide | α-Melanocyte-stimulating hormone (α-MSH), C-terminal fragment |
| Molecular weight | ~341 Da |
| Primary receptor | MC1R (melanocortin receptor 1) |
| Key pathway | NF-κB suppression → reduced TNF-α, IL-6, IL-1β |
| Routes studied | Subcutaneous injection, oral, rectal, topical, nanoparticle delivery |
| Storage | Lyophilized: refrigerate; reconstituted: refrigerate, use within 30 days |
| Reconstitution | Bacteriostatic water |
| Oral bioavailability | Partial — gut tissue activity demonstrated; systemic lower than SubQ |
KPV dosing in research is less standardized than peptides with longer clinical histories. Preclinical data provides the primary reference; research community protocols extrapolate from this. Route of administration matters significantly given KPV's gut-targeting profile.
| Route | Dose Range | Frequency | Primary Use Case |
|---|---|---|---|
| Subcutaneous | 500mcg – 1mg/day | Daily or twice daily | Systemic anti-inflammatory |
| Oral | 1–2mg/day | Daily (with food or fasted) | Gut-targeted inflammation |
| Rectal (suppository/enema) | 0.5–1mg | Daily | Lower GI inflammation (colitis models) |
| Topical | Variable by formulation | 1–2x daily | Skin inflammation research |
For gut-targeted research, oral or rectal delivery gets KPV directly to the target tissue. For systemic anti-inflammatory effects (wound healing, skin, broader inflammation), SubQ injection provides more reliable systemic exposure. Many researchers use SubQ for systemic effects and reserve oral for gut-specific protocols.
KPV commonly comes in 10mg vials. Reconstitute with 2mL bacteriostatic water for a 5mg/mL (5,000 mcg/mL) concentration. At a 500mcg research dose, that's 0.1mL (10 units on a U100 syringe).
| Vial | BAC Water | Concentration | Volume per 500mcg | Volume per 1mg |
|---|---|---|---|---|
| 10mg | 2mL | 5,000 mcg/mL | 0.10mL (10 units) | 0.20mL (20 units) |
| 10mg | 1mL | 10,000 mcg/mL | 0.05mL (5 units) | 0.10mL (10 units) |
The most substantial body of KPV research focuses on colitis models. Studies using dextran sodium sulfate (DSS)-induced colitis in rodents have consistently shown that KPV — whether administered subcutaneously, orally, or rectally — reduces mucosal inflammation, decreases pro-inflammatory cytokine production (particularly TNF-α and IL-6), and improves histological signs of intestinal damage.
Krieger et al. demonstrated that oral KPV in hydrogel nanoparticles produced superior colitis protection compared to free KPV, establishing the principle that targeted colonic delivery amplifies efficacy. This nanoparticle research has since been replicated and extended by multiple groups.
KPV research has shown improvements in tight junction protein expression (ZO-1, occludin, claudins) in intestinal epithelial cell models — the proteins that maintain the barrier between gut contents and bloodstream. This is the cellular mechanism underlying reduced intestinal permeability observed in IBD models.
Topical and local injection KPV studies have demonstrated accelerated wound closure, reduced inflammatory cell infiltration, and improved collagen deposition — effects attributed to the anti-inflammatory reduction of the tissue environment rather than direct growth factor signaling (which differentiates it from BPC-157's wound healing mechanism).
Several studies have directly compared KPV to full-length α-MSH. KPV consistently replicates the anti-inflammatory effects of α-MSH while avoiding the pigmentation and appetite effects of the parent molecule — confirming that the C-terminal tripeptide carries the anti-inflammatory activity selectively.
KPV protocols tend to run 4–8 weeks for acute inflammatory conditions, with some researchers running continuous lower-dose protocols for chronic inflammatory management.
KPV is the fourth component of the KLOW blend (GHK-Cu + BPC-157 + TB-500 + KPV), where it serves as the anti-inflammatory anchor. The rationale: BPC-157 and TB-500 drive tissue repair and healing, GHK-Cu supports collagen remodeling, and KPV suppresses the inflammatory environment that would otherwise inhibit repair processes. The stack is commonly researched for IBD, inflammatory injury recovery, and gut-barrier restoration.
KPV and BPC-157 are frequently combined for gut research specifically. KPV suppresses NF-κB-driven inflammation at the mucosal level; BPC-157 promotes gut epithelial repair through growth factor upregulation and blood vessel formation. The anti-inflammatory environment created by KPV may improve the conditions for BPC-157's repair mechanisms to operate effectively.
KPV has a favorable safety profile in preclinical studies, consistent with its derivation from an endogenous peptide (α-MSH). As a fragment of a naturally occurring hormone, it benefits from the implicit safety context of its parent molecule.
Human safety data is limited compared to compounds with clinical trial histories. KPV has not entered clinical trials as a standalone compound, though its derivation from α-MSH provides an indirect safety reference through the parent molecule's research history.
COA-verified vendor pricing with promo codes. Both S1 Research and Tegridy Research carry KPV.
View Pricing → Dosage Calculator